CERC-301 is a selective NR2B-specific NMDA receptor antagonist being developed for the treatment of Neurogenic Orthostatic Hypotension (nOH) associated with neurodegenerative diseases such as Parkinson's Disease, Multiple Systems Atrophy and Pure Autonomic Failure. CERC-301 has a novel mechanism of action with rapid onset to effect. We believe these attributes may result in improved efficacy and long-term effectiveness with fewer side effects than the leading nOH treatments currently available.
CERC-301 is an orally available, NR2B-specific, NMDA receptor antagonist. NMDA receptor overactivation is associated with many neurodegenerative diseases, including Parkinson's disease. The neural-protective attributes of NMDA receptors antagonists, such as CERC-301, may provide a therapeutic benefit to patients with neurodegenerative conditions. Further investigations to fully understand the therapeutic benefits of NMDA receptor antagonists and the exact mechanism of action of CERC-301 are ongoing.